A Phase 3, Multicenter, Open-Label, Single-Arm Study of MR-130A-01 in Women of Childbearing Potential to Evaluate Contraceptive Efficacy and Safety
Latest Information Update: 11 May 2026
At a glance
- Drugs Norelgestromin (Primary)
- Indications Pregnancy
- Focus Registrational; Therapeutic Use
- Sponsors Mylan Pharmaceuticals
Most Recent Events
- 06 May 2026 Planned End Date changed from 1 Apr 2027 to 1 May 2027.
- 06 May 2026 Planned primary completion date changed from 1 Mar 2027 to 1 May 2027.
- 06 May 2026 Status changed from recruiting to active, no longer recruiting.